Molecular PD-L1 PET/CT Imaging with 89Zr-atezolizumab to Monitor Immune Responses in metastatic Triple Negative Breast Cancer: study protocol for a phase II diagnostic imaging trial. https://www.medrxiv.org/content/10.1101/2023.03.13.23287203
Molecular PD-L1 PET/CT Imaging with 89Zr-atezolizumab to Monitor Immune Responses in metastatic Triple Negative Breast Cancer: study protocol for a phase II diagnostic imaging trial. https://www.medrxiv.org/content/10.1101/2023.03.13.23287203